JPWO2023064707A5 - - Google Patents

Info

Publication number
JPWO2023064707A5
JPWO2023064707A5 JP2024520945A JP2024520945A JPWO2023064707A5 JP WO2023064707 A5 JPWO2023064707 A5 JP WO2023064707A5 JP 2024520945 A JP2024520945 A JP 2024520945A JP 2024520945 A JP2024520945 A JP 2024520945A JP WO2023064707 A5 JPWO2023064707 A5 JP WO2023064707A5
Authority
JP
Japan
Prior art keywords
modified oligonucleotide
modified
alkyl
alkenyl
internucleoside linkage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539596A5 (https=
JP2024539596A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077740 external-priority patent/WO2023064707A1/en
Publication of JP2024539596A publication Critical patent/JP2024539596A/ja
Publication of JP2024539596A5 publication Critical patent/JP2024539596A5/ja
Publication of JPWO2023064707A5 publication Critical patent/JPWO2023064707A5/ja
Pending legal-status Critical Current

Links

JP2024520945A 2021-10-07 2022-10-07 タウ発現を低減するための化合物及び方法 Pending JP2024539596A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163253516P 2021-10-07 2021-10-07
US63/253,516 2021-10-07
US202263317743P 2022-03-08 2022-03-08
US63/317,743 2022-03-08
PCT/US2022/077740 WO2023064707A1 (en) 2021-10-07 2022-10-07 Compounds and methods for reducing tau expression

Publications (3)

Publication Number Publication Date
JP2024539596A JP2024539596A (ja) 2024-10-29
JP2024539596A5 JP2024539596A5 (https=) 2025-10-14
JPWO2023064707A5 true JPWO2023064707A5 (https=) 2025-10-14

Family

ID=85988949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520945A Pending JP2024539596A (ja) 2021-10-07 2022-10-07 タウ発現を低減するための化合物及び方法

Country Status (4)

Country Link
US (1) US20250340872A1 (https=)
EP (1) EP4413138A4 (https=)
JP (1) JP2024539596A (https=)
WO (1) WO2023064707A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4448765A1 (en) 2021-12-13 2024-10-23 Eli Lilly and Company Mapt rna interference agents
WO2025027577A1 (en) * 2023-08-02 2025-02-06 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Micrornas designed against the microtubule-associated protein tau for the treatment of tauopathies
KR20260051070A (ko) 2023-08-10 2026-04-15 하네스 테라퓨틱스 리미티드 기능적 핵산
GB202401412D0 (en) 2024-02-02 2024-03-20 Harness Therapeutics Ltd Functional nucleic acid
US12551569B2 (en) 2024-03-31 2026-02-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use
WO2026002277A1 (zh) * 2024-06-28 2026-01-02 艾码生物科技(南京)有限公司 靶向Tau的RNA干扰方法、核酸及其应用
WO2026010722A1 (en) * 2024-07-03 2026-01-08 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt
WO2026021537A1 (en) * 2024-07-26 2026-01-29 Qilu Pharmaceutical Co., Ltd. iRNA COMPOSITION AND METHOD OF USING SAME
CN118979036B (zh) * 2024-08-01 2025-08-19 北京尧景基因技术有限公司 抑制APP基因表达的siRNA及其缀合物和应用
CN121780524A (zh) * 2024-08-02 2026-04-03 北京尧景基因技术有限公司 抑制MAPT基因表达的siRNA及其缀合物和应用
WO2026067655A1 (zh) * 2024-09-26 2026-04-02 大睿生物医药科技(上海)有限公司 调控TAU表达的dsRNA分子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
AU2016215155A1 (en) * 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
ES2963428T3 (es) * 2016-09-29 2024-03-27 Biogen Ma Inc Compuestos y métodos para reducir la expresión de Tau
AU2021238319A1 (en) * 2020-03-18 2022-10-06 University Of Massachusetts Oligonucleotides for MAPT modulation
AU2021246024A1 (en) * 2020-03-30 2022-10-27 Alnylam Pharmaceuticals, Inc. Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7799103B2 (ja) Ｈｂｖおよびｔｔｒ発現を調節するための組成物および方法
JPWO2023064707A5 (https=)
JP2023052363A5 (https=)
JP7557469B2 (ja) Ａｐｐの発現を低減するための化合物及び方法
JP7315594B2 (ja) Ｌｒｒｋ２発現を低減するための化合物及び方法
JP7167148B2 (ja) Ｓｎｃａ発現を低下させるための化合物及び方法
EP3664816A1 (en) Oligonucleotide compositions and methods thereof
JP2011517676A5 (https=)
JPWO2020132227A5 (https=)
JP7834712B2 (ja) Ｓｃｎ２ａを調節する化合物および方法
JPWO2020190768A5 (https=)
JP2023511895A (ja) Ｓｍｎ２を調節するための化合物及び方法
JP2022188237A (ja) 転写プロセシングの調節のための化合物及び方法
JPWO2021257782A5 (https=)
JP2024523363A (ja) Ｉｆｎａｒ１の発現を低減するための化合物及び方法
JPWO2021195307A5 (https=)
JPWO2022246251A5 (https=)
JPWO2020160163A5 (https=)
JPWO2022159712A5 (https=)
JP2023530072A (ja) Ｐｍｐ２２を調節するための化合物及び方法
JP2026506010A (ja) Ａｐｐ発現を低減するための化合物及び方法
JPWO2021258011A5 (https=)
JP2026506091A (ja) ハンチンチン発現を調節するための対立遺伝子選択的化合物及び方法
JPWO2022266415A5 (https=)
JP2026507572A (ja) アルファ－シヌクレイン発現を調節するための化合物および方法